Biogen
BIIBBiogen is a global biopharmaceutical company dedicated to the discovery, development, and delivery of innovative therapies for serious and complex diseases.
Earnings
Next report
Jul 29, 2026 (In 2 weeks)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
Profile
Biogen is a global biopharmaceutical company dedicated to the discovery, development, and delivery of innovative therapies for serious and complex diseases. The company maintains a leading position in neurology, specialized immunology, and rare diseases, with a primary focus on conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy. Its value proposition centers on advancing a deep pipeline of biological and small molecule treatments through internal research and strategic external collaborations.
A global leader in neuroscience and rare disease therapies with a significant portfolio of market-leading MS and SMA treatments.
Questions, answered.
- What is Biogen's market cap?
- Biogen (BIIB) has a market capitalization of $29.6B and trades on NASDAQ.
- What is Biogen's revenue and profitability?
- Biogen generated $9.9B in trailing twelve-month revenue with net income of $1.4B, representing a net margin of 14.3%. Gross margin stands at 75.5%, with free cash flow of $2.4B. These figures are based on the Q1 2026 filing.
- Who are Biogen's competitors?
- Biogen's key competitors include Organon, Eli Lilly and Company, Roche Group, and others. These companies compete in similar markets and product categories.
- Who does Biogen partner with?
- Biogen's notable partners include Eisai, Genentech, Ionis Pharmaceuticals, and others.
- What subsidiaries does Biogen have?
- Biogen's subsidiaries include Alcyone Therapeutics.
- Where is Biogen headquartered?
- Biogen is headquartered in United States of America and employs approximately 7,570 people. It has been publicly traded since 1991.
